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Lentiviral vectors (LV) have been shown to successfully transfer therapeutic genes into dividing and non-dividing 
cells in laboratory and clinical environments for the benefits of cell and gene therapies. Current LV production 
chiefly relies on a transient transfection method, wherein HEK 293T cells are transfected with 3-4 plasmids. 
Such methods have shown batch to batch variability, and increased costs due to the requirements of 
considerable quantities of cGMP plasmids at clinical stages [1]. This can be circumvented using stable producer 
cell lines, such as the WinPac cell line, that stably harbor all constructs required for vector production and 
reliably output LV vectors over long periods of time [2]. However, the commonly pseudotyped LV envelope 
protein, VSV-G, has difficulty in long term expression and is inactivated by complement [3] and therefore 
alternatives must be sought. Such alternatives can be found in the Cocal-G envelope protein, which can be 
expressed long term, is resistant to complement, and bears similarity to VSV-G whereby both derive within the 
same vesiculovirus genus [4].  
 
A stable LV producer using Cocal-G envelope in the WinPac cell line was produced. Results have illustrated 
that Cocal-G envelope protein expression leads to superinfection of the LV producing cell line, creating long 
term instability due to accumulation of the GFP transgene as determined by qPCR. Such superinfection can be 
prevented by the addition of the non-nucleoside reverse transcriptase inhibitor nevirapine to the cell culture 
media, leading to protection from superinfection in long term culture. The antiviral can subsequently be removed 
by buffer exchange in Vivaspin 4 ultrafiltration cassettes (100,000 MWCO), regenerating infectious titre of LV 
and suggests antiviral addition in upstream production does not negatively impact downstream purification. The 
cocal enveloped producer cell line was therefore robust enough to be scaled up for large scale LV harvesting as 
indicated from scaling to a Corning HYPERFlask system.  
 
This work increases our understanding of how LV envelope design may impact superinfection and ultimately 
specific productivity once cell progress further down a development pathway. In identifying the importance of 
envelope choice and necessary precautions as a result, work can continue to improve stable LV producers, 
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